Zhou F, et al. - In this meta-analysis, researchers examined prospective cohort studies reporting homocysteine as an exposure from patients with cognitive disorders to ascertain the dose-response relationship between blood homocysteine levels and risk of all cause, Alzheimer’s disease, and vascular dementia, as well as cognitive impairment without dementia (CIND). They analyzed 28 prospective cohort studies with 28,257 participants. Among these, 2,557 cases (1,035 all-cause dementia, 530 Alzheimer’s disease, 92 vascular dementia and > 900 CIND) were reported during average follow-up periods ranging from 2.7 to 35 years. A 15% increase in relative risk of Alzheimer-type dementia was observed in linear correlation with every 5 μmol/L increase in blood homocysteine, supporting the existence of an association of a higher concentration of blood homocysteine with a higher risk of Alzheimer-type dementia.